AIM-HIGH was a multi-center clinical trial related to the prophylactic treatment coronary artery disease involving some 90 sites in the United States and Canada, which was conducted between 2006 and 2012 and involved 3,414 volunteers .
The trial was designed to test whether adding high dose, extended-release niacin to simvastatin may be a better than statin therapy alone in reducing long-term cardiovascular events. The participants, who all had a history of cardiovascular disease, were selected according to the following profile: 
The trial was stopped early because there was a demonstrable lack of efficacy for this intervention. The addition of high dose, extended release niacin to a statin did increase HDL cholesterol, as expected, but did not reduce cardiovascular events. The analysis also showed that there was little to no probability that adding high-dose, extended release niacin to statin treatment would show a benefit even if the study continued to its originally planned completion.
Up to date info
Latest research - AIM-HIGH trial
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on AIM-HIGH trial for any updates.